Diffusion imaging changes in grey matter in Alzheimer's disease: A potential marker of early neurodegeneration

Alzheimer's Research and Therapy

Volumn 7, Issue 1, 2015, Pages

  Weston, Philip S J ^a   Simpson, Ivor J A ^a,b   Ryan, Natalie S ^a   Ourselin, Sebastien ^a,b   Fox, Nick C ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; AUTOSOMAL DOMINANT DISORDER; DEMENTIA; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; GENE MUTATION; GRAY MATTER; HIPPOCAMPUS; HUMAN; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; POSTERIOR CINGULATE; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SYMPTOM; SYSTEMATIC REVIEW;

EID: 84933519430     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-015-0132-3     Document Type: Review

References (55)

1. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795-804.
2. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357-67.
3. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol. 2012;69:1002-10.
4. Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012;8:261-71.
5. Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther. 2011;3:1.
6. Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med. 2013;368:1169-71.
7. Jack Jr CR, Petersen RC, O'Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology. 1992;42:183-8.
8. Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM, Stevens JM, et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain. 1996;119:2001-7.
9. Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, et al. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol. 2006;5:828-34.
10. Van Petten C. Relationship between hippocampal volume and memory ability in healthy individuals across the lifespan: review and meta-analysis. Neuropsychologia. 2004;42:1394-413.
11. Jack Jr CR, Shiung MM, Weigand SD, O'Brien PC, Gunter JL, Boeve BF, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology. 2005;65:1227-31.
12. Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19:497-510.
13. Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology. 2009;72:1048-55.
14. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis, I. Segmentation and surface reconstruction. Neuroimage. 1999;9:179-94.
15. Le Bihan D. Looking into the functional architecture of the brain with diffusion MRI. Nat Rev Neurosci. 2003;4:469-80.
16. Ulug AM, Moore DF, Bojko AS, Zimmerman RD. Clinical use of diffusion-tensor imaging for diseases causing neuronal and axonal damage. AJNR Am J Neuroradiol. 1999;20:1044-8.
17. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Weigand SD, O'Brien PC, et al. DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology. 2005;64:902-4.
18. Muller MJ, Greverus D, Dellani PR, Weibrich C, Wille PR, Scheurich A, et al. Functional implications of hippocampal volume and diffusivity in mild cognitive impairment. Neuroimage. 2005;28:1033-42.
19. Ringman JM, O'Neill J, Geschwind D, Medina L, Apostolova LG, Rodriguez Y, et al. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain. 2007;130:1767-76.
20. Bozzali M, Falini A, Franceschi M, Cercignani M, Zuffi M, Scotti G, et al. White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry. 2002;72:742-6.
21. Takahashi S, Yonezawa H, Takahashi J, Kudo M, Inoue T, Tohgi H. Selective reduction of diffusion anisotropy in white matter of Alzheimer disease brains measured by 3.0 Tesla magnetic resonance imaging. Neurosci Lett. 2002;332:45-8.
22. Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl. 1998;53:127-40.
23. Walhovd KB, Fjell AM, Amlien I, Grambaite R, Stenset V, Bjornerud A, et al. Multimodal imaging in mild cognitive impairment: metabolism, morphometry and diffusion of the temporal-parietal memory network. Neuroimage. 2009;45:215-23.
24. Josephs KA, Whitwell JL, Ahmed Z, Shiung MM, Weigand SD, Knopman DS, et al. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol. 2008;63:204-12.
25. Demaerel P, Heiner L, Robberecht W, Sciot R, Wilms G. Diffusion-weighted MRI in sporadic Creutzfeldt-Jakob disease. Neurology. 1999;52:205-8.
26. Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132:2659-68.
27. Bozzali M, Cercignani M, Sormani MP, Comi G, Filippi M. Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. AJNR Am J Neuroradiol. 2002;23:985-8.
28. Chiapponi C, Piras F, Piras F, Fagioli S, Caltagirone C, Spalletta G. Cortical grey matter and subcortical white matter brain microstructural changes in schizophrenia are localised and age independent: a case-control diffusion tensor imaging study. PLoS One. 2013;8, e75115.
29. Muller MJ, Mazanek M, Weibrich C, Dellani PR, Stoeter P, Fellgiebel A. Distribution characteristics, reproducibility, and precision of region of interest-based hippocampal diffusion tensor imaging measures. AJNR Am J Neuroradiol. 2006;27:440-6.
30. Muller MJ, Greverus D, Weibrich C, Dellani PR, Scheurich A, Stoeter P, et al. Diagnostic utility of hippocampal size and mean diffusivity in amnestic MCI. Neurobiol Aging. 2007;28:398-403.
31. Fellgiebel A, Dellani PR, Greverus D, Scheurich A, Stoeter P, Muller MJ. Predicting conversion to dementia in mild cognitive impairment by volumetric and diffusivity measurements of the hippocampus. Psychiatry Res. 2006;146:283-7.
32. Douaud G, Menke RA, Gass A, Monsch AU, Rao A, Whitcher B, et al. Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease. J Neurosci. 2013;33:2147-55.
33. Rose SE, Janke AL, Chalk JB. Gray and white matter changes in Alzheimer's disease: a diffusion tensor imaging study. J Magn Reson Imaging. 2008;27:20-6.
34. Scola E, Bozzali M, Agosta F, Magnani G, Franceschi M, Sormani MP, et al. A diffusion tensor MRI study of patients with MCI and AD with a 2-year clinical follow-up. J Neurol Neurosurg Psychiatry. 2010;81:798-805.
35. Kantarci K, Avula R, Senjem ML, Samikoglu AR, Zhang B, Weigand SD, et al. Dementia with Lewy bodies and Alzheimer disease: neurodegenerative patterns characterized by DTI. Neurology. 2010;74:1814-21.
36. Jacobs HI, van Boxtel MP, Gronenschild EH, Uylings HB, Jolles J, Verhey FR. Decreased gray matter diffusivity: a potential early Alzheimer's disease biomarker? Alzheimers Dement. 2013;9:93-7.
37. Kantarci K, Senjem ML, Avula R, Zhang B, Samikoglu AR, Weigand SD, et al. Diffusion tensor imaging and cognitive function in older adults with no dementia. Neurology. 2011;77:26-34.
38. Ryan NS, Keihaninejad S, Shakespeare TJ, Lehmann M, Crutch SJ, Malone IB, et al. Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease. Brain. 2013;136:1399-414.
39. Fortea J, Sala-Llonch R, Bartres-Faz D, Bosch B, Llado A, Bargallo N, et al. Increased cortical thickness and caudate volume precede atrophy in PSEN1 mutation carriers. J Alzheimers Dis. 2010;22:909-22.
40. Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodriguez Martinez De Llano S, Edison P, et al. Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain. 2011;134:293-300.
41. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:6174-84.
42. Alexander DC, Pierpaoli C, Basser PJ, Gee JC. Spatial transformations of diffusion tensor magnetic resonance images. IEEE Trans Med Imaging. 2001;20:1131-9.
43. Andersson JL, Skare S. A model-based method for retrospective correction of geometric distortions in diffusion-weighted EPI. Neuroimage. 2002;16:177-99.
44. Larkman DJ, Hajnal JV, Herlihy AH, Coutts GA, Young IR, Ehnholm G. Use of multicoil arrays for separation of signal from multiple slices simultaneously excited. J Magn Reson Imaging. 2001;13:313-7.
45. Sotiropoulos SN, Jbabdi S, Xu J, Andersson JL, Moeller S, Auerbach EJ, et al. Advances in diffusion MRI acquisition and processing in the Human Connectome Project. Neuroimage. 2013;80:125-43.
46. Feinberg DA, Setsompop K. Ultra-fast MRI of the human brain with simultaneous multi-slice imaging. J Magn Reson. 2013;229:90-100.
47. Zhang H, Schneider T, Wheeler-Kingshott CA, Alexander DC. NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. Neuroimage. 2012;61:1000-16.
48. Assaf Y, Basser PJ. Composite hindered and restricted model of diffusion (CHARMED) MR imaging of the human brain. Neuroimage. 2005;27:48-58.
49. Fellgiebel A, Yakushev I. Diffusion tensor imaging of the hippocampus in MCI and early Alzheimer's disease. J Alzheimers Dis. 2011;26 Suppl 3:257-62.
50. Barbagallo G, Nicoletti G, Cherubini A, Trotta M, Tallarico T, Chiriaco C, et al. Diffusion tensor MRI changes in gray structures of the frontal-subcortical circuits in amyotrophic lateral sclerosis. Neurol Sci. 2014;35:911-8.
51. Cardoso JM, Leung K, Modat M, Keihaninejad S, Cash D, Barnes J, et al. STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcelation. Med Image Anal. 2013;17:671-84.
52. Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet. 2001;358:201-5.
53. Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, et al. Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol. 2011;95:579-93.
54. Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20:6-15.
55. Jack Jr CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119-28.